^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer.
Published date:
05/26/2022
Excerpt:
Pts who have received at least once platinum-based chemotherapy, recurrent advanced cervical cancer, PD-L1 for CPS≥1, ECOG 0-1 were considered...In the efficacy-evaluable patients (n = 39), the ORR was 59% (95% CI 42.1% to 74.4%) and the DCR was 94.9% (95% CI 82.7% to 99.4%). The median PFS was 9.46 months (95% CI 8.2 to 11.9) and the 6-month PFS rate was 73.4% (95% CI 60.6% to 89.0%)...Anlotinib plus sintilimab showed a long-term survival benefit for patients with recurrent advanced cervical cancer.
DOI:
10.1200/JCO.2022.40.16_suppl.5536
Source:
Title:
Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
Published date:
02/22/2022
Excerpt:
We investigated the efficacy and safety of sintilimab plus anlotinib as second-line or later therapy for PD-L1–positive recurrent or metastatic (R/M) CA....The ORR was 54.8% (95% CI, 38.7 to 70.2). In 39 efficacy-evaluable patients, the ORR was 59.0% (95% CI, 42.1 to 74.4); the disease control rate was 94.9% (95% CI, 82.7 to 99.4). The median PFS was 9.4 months (95% CI, 8.0 to 14.6)…Sintilimab plus anlotinib as second-line or later therapy is efficacious and safe for patients with advanced CA who have failed prior chemotherapy.
DOI:
10.1200/JCO.21.02091
Source:
Title:
Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
Published date:
05/19/2021
Excerpt:
In the efficacy-evaluable population (n = 39), the therapeutic evaluation showed that 2 and 20 patients achieved complete response and partial response respectively, yielding the ORR of 56.4% (22/39, 95% CI:40.2 to 71.5). The DCR was 94.9% (37/39, 95% CI:80.7 to 98.8)...Anlotinib plus sintilimab showed a promising efficacy with a favorable toxicity profile for patients with recurrent advanced cervical cancer.
DOI:
10.1200/JCO.2021.39.15_suppl.5524
Source:
Title:
865P - A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent, or metastatic cervical cancer (CC)
Published date:
09/14/2020
Excerpt:
From September 2019 to April 2020, 16 patients were recruited with a median age of 52 years (range:36-67), FIGO histopathological stage I (6.3%), II (43.7%), III (25%), IV (6.3%) or undiagnosed (18.7%) were enrolled. Among these patients, 11 were evaluable. The therapeutic evaluation showed the incidence of complete response, partial response, stable disease and progressive disease was 9.1%, 45.5%, 45.5% and 0%, respectively, yielding an ORR of 54.5% and DCR of 100%...Anlotinib plus sintilimab showed promising efficacy with a favourable toxicity profile for patients with persistent, recurrent, or metastatic cervical cancer.
